Exanatide Amylin/Eli Lilly

Current Opinion in Investigational Drugs

Volumn 4, Issue 4, 2003, Pages 459-465

  Giannoukakis, Nick ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 AGONIST; GLUCOSE; HELODERMA SUSPECTUM VENOM; INSULIN; LY 307161; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; SULFONYLUREA DERIVATIVE; SYNTHETIC EXENDIN 4; UNCLASSIFIED DRUG; ANTIOBESITY AGENT; PEPTIDE; VENOM;

AREA UNDER THE CURVE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIABETES MELLITUS; DIET THERAPY; DISEASE SEVERITY; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG INDICATION; DRUG ISOLATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RELEASE; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MICROENCAPSULATION; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACODYNAMICS; REVIEW; STOMACH EMPTYING; STRUCTURE ACTIVITY RELATION; ANIMAL; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; OBESITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL;

ANIMALS; ANTI-OBESITY AGENTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; OBESITY; PEPTIDES; STRUCTURE-ACTIVITY RELATIONSHIP; VENOMS;

EID: 0038545342     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. 15082 Isolation and characterization of rat 3Y1 fibroblast clones overexpressing the src homology region of phospholipase C-γ 2. Homma Y, Emori Y, Takenawa T J Biol Chem 1992 267 6 3778-3782
2. 207996 TheraTech Inc Annual Report 1995. TheraTech Inc 1995
3. 221112 Amylin Pharmaceuticals acquires rights to potential diabetes drug derived from Gila monster venom. Amylin Pharmaceuticals Inc Press Release 1996 October 07
4. 254049 Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats. Barragan JM, Rodriguez RE, Eng J, Blazquez E Regul Pept 1996 67 1 63-68
5. 254055 Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β-cells. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Goke B J Biol Chem 1993 268 26 19650-19655 Reports the stimulation of insulin secretion in the presence of hyperglycemia by exendin-4. Truncated exendin (9-39) amide is a specific inhibitor for both exendin-4 and for GLP-1.
6. 290984 American Diabetes Association 58th Annual Meeting and Scientific Sessions Chicago, IL, USA. Luo J IDDB Meeting Report 1998 June 13-16
7. 298335 Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. Chen YE, Drucker DJ J Biol Chem 1997 272 7 4108-4115
8. 298337 Molecular cloning of the helodermin and exendin-4 cDNAs: Evidence against the existence of mammalian homologues. Pohl M, Wank SA Gastroenterology 1997 112 4 Suppl A1181
9. 2-truncated exendin-4 analogs.
10. 298349 Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Kollings F, Fehmann HC, Goeke R, Goeke B Diabetes 1995 44 1 16-19 Demonstration that exendin-4 stimulates insulin secretion in vivo.
11. 298351 Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Thorens B, Porret A, Buhler L, Deng SP, Morel P, Widmann C Diabetes 1993 42 11 1678-1682 Demonstration that exendin-4 stimulates insulin secretion at the human islet GLP-1 receptor in vitro.
12. 301884 Amylin Pharmaceuticals reports successful phase I study of exendin-4, diabetes drug candidate. Amylin Pharmaceuticals Inc Press Release 1998 October 20 Amylin reports results of a first safety and tolerability study of exendin-4 in humans.
13. 306812 Glucagon-like peptides. Drucker DJ Diabetes 1998 47 2 159-169 Review of GLP-1 and exendins.
14. 311445 Amylin Pharmaceuticals files IND for AC-2993 (synthetic exendin-4); Reports on feasibility of non-injectable routes of delivery. Amylin Pharmaceuticals Inc Press Release 1999 January 13 Amylin announces that it has filed an IND for exendin-4 in anticipation of a first clinical trial in type 2 diabetic patients and that exedin-4 was found to be biologically active when administered via non-injectable routes.
15. 315200 Isolation and characterization of exendin-4, an exendin-3 analog from Heloderma suspectum venom. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP J Biol Chem 1992 267 11 7402-7405
16. 315205 Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Greig NH, Holloway HW, De Ore KA, Jani D, Wang Y, Zhou J, Garant MJ, Egan JM Diabetologia 1999 42 1 45-50
17. 315206 Influence of glucagon-like peptide 1 on fasting glucose glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Nauck MA, Sauerwald A, Ritzel R, Holst JJ, Schmiegel W Diabetes Care 1998 21 11 1925-1931 Study demonstrating the activity of GLP-1 in sulfonylurea secondary failure patients.
18. 315207 Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ Diabetologia 1998 41 3 271-278
19. 315208 Comparison of the glucose-lowering effects of exendin-4 and GLP-1 in diabetic db/db mice. Bhavasar SP, Watkins JJ, Young AA Diabetes 1998 47 Suppl 1 746
20. 315209 Dose-response for glucose lowering by exendin-4 in diabetic rhesus monkeys (Macaca mulatta). Bodkin N, Hansen B, Young AA Diabetes 1998 47 Suppl 1 361
21. 315210 Exendin-4 decreases hemoglobin A1c in diabetic fatty Zucker rats. Gedulin BR, Jodka C, Hoyt JA, Lawler R, Young AA Diabetes 1998 47 Suppl 1 1085
22. 329671 American Diabetes Association - 59th Annual Meeting San Diego, CA, USA. Hopfner R IDDB Meeting Report 1999 June 19-22
23. 337550 Amylin Pharmaceuticals acquires patent rights for exendin-4 gene. Amylin Pharmaceuticals Inc Press Release 1999 August 23
24. 344745 Glucose-lowering and insulin-sensitizing actions of exendin-4: Studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, Denaro M Diabetes 1999 48 5 1026-1034 A preclinical study which compares the effects of GLP-1 and exendin-4 in several animal models of diabetes.
25. 352024 Product Pipeline: AC2993. Amylin Pharmaceuticals Inc Company World Wide Web Site 2000 January 11
26. 366516 Amylin Pharmaceuticals and Alkermes sign agreement for development of long-acting formulation of AC2993 (synthetic exendin-4). Amylin Pharmaceuticals Inc Press Release 2000 May 15
27. 369298 Effects of five-day dosing of synthetic exendin-4 (AC2993) in people with type 2 diabetes. Buse J, Fineman M, Gottleib A, Gaines E, Kolterman O Diabetes 2000 49 Suppl 1 Abs 402-P
28. 369579 Dose-response for postprandial glucose-lowering effect of synthetic exendin-4 (AC2993) in subject with type 2 diabetes. Fineman M, Young A, Gaines E, Prickett K Diabetes 2000 49 Suppl 1 Abs 427-P
29. 369651 Dose-response for inhibition of glucagon secretion and gastric emptying by synthetic exendin-4 (AC2993) in subjects with type 2 diabetes. Kolterman O, Gottlieb A, Prickett K, Gaines E, Young A Diabetes 2000 49 Suppl 1 Abs 460-P
30. 369981 Hypoglycemic override of inhibition of gastric emptying by exendin-4. Jodka C, Parkes D, Young A Diabetes 2000 49 Suppl 1 Abs 1187-P
31. 388319 Amylin Pharmaceuticals initiates phase II study of diabetes drug candidate AC2993 in type II diabetes to support start of phase III in 2001. Amylin Pharmaceuticals Inc Press Release 2000 November 02
32. 396468 JP Morgan Hambrecht & Quist 19th Annual Healthcare Conference (Part IV) San Francisco, CA, USA. Hookes J IDDB Meeting Report 2001 January 8-11
33. 402351 Amylin Pharmaceuticals obtains license from NIH for novel use of exendin-4. Amylin Pharmaceuticals Inc Press Release 2001 March 19
34. 408388 Sustained expression of exendin-4 does not perturb glucose homeostasis, β-cell mass, or food intake in metallothionein-preproexendin transgenic mice. Baggio L, Adatia F, Bock T, Brubaker PL, Drucker DJ J Biol Chem 2000 275 44 34471-3447
35. 408391 Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Szayna M, Doyle ME, Betkey JA, Holloway HW, Spencer RG, Greig NH, Egan JM Endocrinology 2000 141 6 1936-1941
36. 408397 Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Zhou J, Wang X, Pineyro MA, Egan JM Diabetes 1999 48 12 2358-2366
37. 408400 Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Xu G, Stoffers DA, Habener JF, Bonner-Weir S Diabetes 1999 48 12 2270-2276
38. 413370 Amylin Pharmaceuticals presents positive results from AC2993 (synthetic exendin-4) one-month study in type II diabetes at American Diabetes Association Annual Meeting. Amylin Pharmaceuticals Inc Press Release 2001 June 22
39. 413888 American Diabetes Association - 61st Scientific Sessions (Part V), Philadelphia, PA, USA. Patterson C IDDB Meeting Report 2001 June 22-26
40. 414671 Novo Nordisk development pipeline, updated quarterly. Company World Wide Web Site July 06 2001
41. 415122 American Diabetes Association - 61st Scientific Sessions (Part VI), Philadelphia, PA, USA. Hopfner R IDDB Meeting Report 2001 June 22-26
42. 432359 Amylin Pharmaceuticals announces two abstracts accepted by American Society for Clinical Pharmacology and Therapeutics for 2002 annual meeting. Amylin Pharmaceuticals Inc Press Release 2001 December 05
43. 432922 Amylin Pharmaceuticals initiates first phase 3 pivotal trial of AC2993 (synthetic exendin-4) in type 2 diabetes. Amylin Pharmaceuticals Inc Press Release 2001 December 10
44. 434384 Zealand Pharmaceuticals in clinical trials with anti-diabetic. Zealand Pharmaceuticals Press Release 2001 December 20
45. 437942 Amylin Pharmaceuticals initiates second phase III pivotal trial of AC2993 (synthetic exendin-4) in type II diabetes. Amylin Pharmaceuticals Inc Press Release 2002 January 30
46. 443501 Amylin Pharmaceuticals initiates third phase III pivotal trial of AC2993 (synthetic exendin-4) in type II diabetes. Amylin Pharmaceuticals Inc Press Release 2002 March 14
47. 443509 Amylin Pharmaceuticals: Uniquely positioned with two late-stage, first-in-class diabetes product candidates. Amylin Pharmaceuticals Inc Company Presentation 2002 February 26
48. 457323 ConjuChem announces start of phase I trial for DAC:GLP-1, a type II diabetes drug candidate. ConjuChem Inc Press Release 2002 July 08
49. 464652 European Association for the Study of Diabetes - 38th Annual Meeting (Part II), Budapest, Hungary. Van Der Wal PS IDDB Meeting Report 2002 September 1-5
50. 464704 Lilly and Amylin to collaborate on potential breakthrough diabetes treatment. Eli Lilly & Co, Amylin Pharmaceuticals Inc Press Release 2002 September 20
51. 465091 Theratechnologies expands peptide portfolio in endocrinology with the addition of a GLP-1 program for the treatment of type II diabetes. Theratechnologies Inc Press Release 2002 September 25
52. 468113 Amylin and Lilly announce completion of enrollment for first phase III pivotal trial of AC2993 (synthetic Exendin-4) in type II diabetes. Amylin Pharmaceuticals Inc, Eli Lilly & Co Press Release 2002 October 28
53. 468714 AC2993 (synthetic Exendin-4): A potential new anti-diabetic agent. SMI Conference - Diabetes 2002 28-29 October
54. 476858 Population modeling to guide phase 3 dose selection for AC2993 (synthetic exendin-4). Phillips L, Fineman M, Taylor K, Baron A, Ludwig E, Grasela T Clin Pharmacol Ther 2002 71 2 P29
55. 476860 Unique study design: Evaluation of the effect of dose titration on dose-limiting nausea. Fineman MS, Shen L, Smitzi J, Aisporna M, Bicsak T, Taylor K, Baron A Clin Pharmacol Ther 2002 71 2 P19
56. 476863 28 Days of treatment with AC2993 (synthetic exendin-4) improved glycemic control in patients with type 2 diabetes concomitantly treated with metformin (met) and/or sulfonylurea (sfu). Fineman M, Bicsak T, Shen L, Taylor K, Gaines E, Varns A, Kim D, Baron A Diabetologia 2002 45 Suppl 2 Abs 124
57. 477962 Genetic determinants of non-insulin dependent diabetes mellitus: Strategies and recent results. Velho G, Froguel P Diabetes Metab Rev 1997 23 1 7-17
58. 477963 Glucokinase and MODY: From the gene to the disease. Froguel P Diabetic Med 1996 13 9 Suppl 6 S96-S97
59. 477964 Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. DeFronzo RA, Ferrannini E Diabetes Care 1991 14 3 173-194
60. 477965 Pathogenesis of NIDDM. A balanced overview. DeFronzo RA, Bonadonna RC, Ferrannini E Diabetes Care 1992 15 3 318-368
61. 477966 Glucose transport and NIDDM. Garvey WT Diabetes Care 1992 15 3 396-417
62. 477967 Treatment of type 2 diabetes mellitus: Pharmacologic intervention. McCormick M, Quinn L J Cardiovasc Nurs 2002 16 2 55-67
63. 478017 Pharmacologic therapy for type 2 diabetes mellitus. DeFronzo RA Ann Intern Med 2000 133 1 73-74
64. 478018 Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus. Baron AD, Kim D, Weyer C Curr Drug Targets 2002 2 1 63-82
65. 478020 Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. Egan JM, Meneilly GS, Habener JF, Elahi D J Clin Endocrinol Metab 2002 87 8 3768-3773
66. 478023 The insulinotropic effect of acute exendin-4 administered to humans: Comparison of nondiabetic state to type 2 diabetes. Egan JM, Clocquet AR, Elahi D J Clin Endocrinol Metab 2002 87 3 1282-1290
67. 478025 Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Parkes DG, Pittner R, Jodka C, Smith P, Young A Metabolism 2001 50 5 583-589
68. 478028 Glucagon-like peptide-1: A major regulator of pancreatic β-cell function. Perfetti R, Merkel P Eur J Endocrinol 2000 143 6 717-725
69. 478029 Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP J Biol Chem 1992 267 11 7402-7405
70. 478030 Exendin-4 differentiation of a human pancreatic duct cell line into endocrine cells: Involvement of PDX-1 and HNF3β transcription factors. Zhou J, Pineyro MA, Wang X, Doyle ME, Egan JM J Cell Physiol 2002 192 3 304-314
71. 478031 The entero-insular axis in type 2 diabetes - Incretins as therapeutic agents. Creutzfeldt W Exp Clin Endocrinology Diabetes 2001 109 2 S288-S303
72. 478032 Exendin 4 up-regulates expression of PDX 1 and hastens differentiation and maturation of human fetal pancreatic cells. Movassat J, Beattie GM, Lopez AD, Hayek A J Clin Endocrinol Metab 2002 87 10 4775-4781
73. 478033 Exendin-4 as a stimulator of rat insulin I gene promoter activity via bZIP/CRE interactions sensitive to serine/threonine protein kinase inhibitor Ro 31-8220. Chepurny OG, Hussain MA, Holz GG Endocrinology 2002 143 6 2303-2313
74. 478425 Pharmacologic treatment of type II diabetes mellitus: Realities and perspectives. Abdallah MP, Hirbli K J Med Libanais 1999 47 4 233-237
75. 478648 Continuous subcutaneous infusion of AC2993 (synthetic exendin-4) provides sustained day-long glycemic control in patients with type II diabetes. Taylor K, Kim D, Bicsak T, Heintz S, Varns A, Aisporna M, Fineman M, Baron A Diabetologia 2002 45 Abs 123
76. 478649 Once-daily administration of LY307161 SR, a sustained release formulation of a GLP-1 analogue, substantially reduces fasting and daytime glucose levels in patients with type II diabetes. Trautmann ME, Kapitza C, Hompesch M, Heise T, Mace KF, Patterson B Diabetologia 2002 45 Abs 121
77. 489499 Amylin Pharmaceuticals Inc: Amylin annual income statement. Harr S, Husseini N, Wheeler J Morgan Stanley Dean Witter 2003 February 2003